` EXEL (Exelixis Inc) vs S&P 500 Comparison - Alpha Spread

EXEL
vs
S&P 500

Over the past 12 months, EXEL has significantly outperformed S&P 500, delivering a return of 113% compared to the S&P 500's 12% growth.

Stocks Performance
EXEL vs S&P 500

Loading

Performance Gap
EXEL vs S&P 500

Loading
EXEL
S&P 500
Difference

Performance By Year
EXEL vs S&P 500

Loading
EXEL
S&P 500
Add Stock

Competitors Performance
Exelixis Inc vs Peers

S&P 500
EXEL
ABBV
AMGN
GILD
VRTX
Add Stock

Exelixis Inc
Glance View

Economic Moat
Wide
Market Cap
12.6B USD
Industry
Biotechnology

Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine. The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.

EXEL Intrinsic Value
29.08 USD
Overvaluation 35%
Intrinsic Value
Price
Back to Top